Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Br J Cancer
Springer Science and Business Media LLC
MetadataShow full item record
Mossop, H., Grayling, M. J., Gallagher, F., Welsh, S., Stewart, G., & Wason, J. M. (2021). Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.. Br J Cancer https://doi.org/10.1038/s41416-021-01613-5
BACKGROUND: Efficient trial designs are required to prioritise promising drugs within Phase II trials. Adaptive designs are examples of such designs, but their efficiency is reduced if there is a delay in assessing patient responses to treatment. METHODS: Motivated by the WIRE trial in renal cell carcinoma (NCT03741426), we compare three trial approaches to testing multiple treatment arms: (1) single-arm trials in sequence with interim analyses; (2) a parallel multi-arm multi-stage trial and (3) the design used in WIRE, which we call the Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design. The MASTER design recruits patients to one arm at a time, pausing recruitment to an arm when it has recruited the required number for an interim analysis. We conduct a simulation study to compare how long the three different trial designs take to evaluate a number of new treatment arms. RESULTS: The parallel multi-arm multi-stage and the MASTER design are much more efficient than separate trials. The MASTER design provides extra efficiency when there is endpoint delay, or recruitment is very quick. CONCLUSIONS: We recommend the MASTER design as an efficient way of testing multiple promising cancer treatments in non-comparative Phase II trials.
Cancer Research UK Cambridge Centre [C9685/A25177]
Cancer Research UK (C96/A25177)
External DOI: https://doi.org/10.1038/s41416-021-01613-5
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329684
All rights reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved